SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Adaptimmune Therapeutics Q1 EPS $(0.040) Beats $(0.250) Estimate, Sales $761.000K

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.040) per share which beat the analyst consensus estimate of $(0.250) by 84 percent. This is unchanged from the same period last year. The company

Benzinga · 05/14/2020 11:32

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.040) per share which beat the analyst consensus estimate of $(0.250) by 84 percent. This is unchanged from the same period last year. The company reported quarterly sales of $761.000 thousand which missed the analyst consensus estimate of $23.290 million by 96.73 percent.